News und Analysen
![Pharnext to Host Research and Development Day on October 13, 2020](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Pharnext to Host Research and Development Day on October 13, 2020
Pharnext to Host Research and Development Day on October 13, 2020
![DGAP-News: Abivax presents first-half 2020 financial results and operations update](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
DGAP-News: Abivax presents first-half 2020 financial results and operations update
DGAP-News: Abivax presents first-half 2020 financial results and operations update
![DGAP-News: Abivax gibt Halbjahresergebnisse 2020 und Update zur Unternehmensentwicklung bekannt](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
DGAP-News: Abivax gibt Halbjahresergebnisse 2020 und Update zur Unternehmensentwicklung bekannt
DGAP-News: Abivax gibt Halbjahresergebnisse 2020 und Update zur Unternehmensentwicklung bekannt
![Pharnext and the Charcot-Marie-Tooth Association Enter Biomarker Research Collaboration](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Pharnext and the Charcot-Marie-Tooth Association Enter Biomarker Research Collaboration
Pharnext and the Charcot-Marie-Tooth Association Enter Biomarker Research Collaboration
![DGAP-News: ABIVAX: Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
DGAP-News: ABIVAX: Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study
DGAP-News: ABIVAX: Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study
![DGAP-News: Abivax gibt 2-Jahres-Daten zur Langzeitwirkung und Sicherheit aus der Phase-2a-Erhaltungsstudie mit ABX464 zur Behandlung von Colitis ulcerosa bekannt](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: Abivax gibt 2-Jahres-Daten zur Langzeitwirkung und Sicherheit aus der Phase-2a-Erhaltungsstudie mit ABX464 zur Behandlung von Colitis ulcerosa bekannt
DGAP-News: Abivax gibt 2-Jahres-Daten zur Langzeitwirkung und Sicherheit aus der Phase-2a-Erhaltungsstudie mit ABX464 zur Behandlung von Colitis ulcerosa bekannt
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![Sartorius Stedim Biotech SA: Information on Document Availability](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA: Information on Document Availability
![Pharnext announces approval of resolutions at its Annual General Meeting of 17 July 2020](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Pharnext announces approval of resolutions at its Annual General Meeting of 17 July 2020
Pharnext announces approval of resolutions at its Annual General Meeting of 17 July 2020
![Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont
Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![DGAP-News: Abivax behandelt ersten Patienten in der klinischen Phase 2b/3-Covid-19-Studie mit ABX464](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-News: Abivax behandelt ersten Patienten in der klinischen Phase 2b/3-Covid-19-Studie mit ABX464
DGAP-News: Abivax behandelt ersten Patienten in der klinischen Phase 2b/3-Covid-19-Studie mit ABX464
![DGAP-News: Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial
DGAP-News: Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial
![DGAP-News: Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
DGAP-News: Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting
DGAP-News: Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting
![DGAP-News: Abivax gibt Update zu jüngsten Unternehmenserfolgen und verkündet positive Ergebnisse seiner ordentlichen und außerordentlichen Jahreshauptversammlung](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
DGAP-News: Abivax gibt Update zu jüngsten Unternehmenserfolgen und verkündet positive Ergebnisse seiner ordentlichen und außerordentlichen Jahreshauptversammlung
DGAP-News: Abivax gibt Update zu jüngsten Unternehmenserfolgen und verkündet positive Ergebnisse seiner ordentlichen und außerordentlichen Jahreshauptversammlung
![DGAP-News: ABIVAX: Abivax receives € 5m non-dilutive financing from Société Générale as State Guaranteed Loan](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: ABIVAX: Abivax receives € 5m non-dilutive financing from Société Générale as State Guaranteed Loan
DGAP-News: ABIVAX: Abivax receives € 5m non-dilutive financing from Société Générale as State Guaranteed Loan
![DGAP-News: Abivax erhält nicht-verwässernde Finanzierung in Höhe von EUR 5 Mio. als staatlich gesichertes Darlehen von Société Générale](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
DGAP-News: Abivax erhält nicht-verwässernde Finanzierung in Höhe von EUR 5 Mio. als staatlich gesichertes Darlehen von Société Générale
DGAP-News: Abivax erhält nicht-verwässernde Finanzierung in Höhe von EUR 5 Mio. als staatlich gesichertes Darlehen von Société Générale
![Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020
Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020
![Pharnext provides regulatory and clinical update on PXT3003 Phase III study for the treatment of Charcot-Marie-Tooth Type 1A](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Pharnext provides regulatory and clinical update on PXT3003 Phase III study for the treatment of Charcot-Marie-Tooth Type 1A
Pharnext provides regulatory and clinical update on PXT3003 Phase III study for the treatment of Charcot-Marie-Tooth Type 1A
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![DGAP-News: Abivax veröffentlicht Referenzdokument 2020 'Document d'Enregistrement Universel'](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
DGAP-News: Abivax veröffentlicht Referenzdokument 2020 'Document d'Enregistrement Universel'
DGAP-News: Abivax veröffentlicht Referenzdokument 2020 'Document d'Enregistrement Universel'
![DGAP-News: Abivax publishes universal registration document 2020 'Document d'Enregistrement Universel'](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
DGAP-News: Abivax publishes universal registration document 2020 'Document d'Enregistrement Universel'
DGAP-News: Abivax publishes universal registration document 2020 'Document d'Enregistrement Universel'
![DGAP-News: Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
DGAP-News: Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial
DGAP-News: Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial
![DGAP-News: Abivax erhält Genehmigung der deutschen Arzneimittelzulassungsbehörde für klinische ABX464 Phase-2b/3-COVID-19-Studie](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
DGAP-News: Abivax erhält Genehmigung der deutschen Arzneimittelzulassungsbehörde für klinische ABX464 Phase-2b/3-COVID-19-Studie
DGAP-News: Abivax erhält Genehmigung der deutschen Arzneimittelzulassungsbehörde für klinische ABX464 Phase-2b/3-COVID-19-Studie